Saudi Arabia launches winter census of water birds in Farasan reserve
FARASAN — The National Center for Wildlife (NCW) has launched annual winter census of water birds in Farasan Islands Reserve, as part of its efforts to monitor the numbers of migratory birds, assess the health of wetland ecosystems, and take appropriate measures to protect biodiversity and enhance its sustainability.
The environmental survey will record more than 10,000 water birds from 45 different species, such as the pink-backed pelican, the giant heron, the white-eyed gull, the terns, and the plovers, in view of the prominent environmental role of Farasan Islands as one of the main stations for migratory birds in Saudi Arabia.
The CEO of NCW, Dr. Muhammad Ali Qurban, explained that the winter census of water birds is a major scientific step to monitor environmental changes and enhance Saudi Arabia's efforts to protect biodiversity. Saudi Arabia is committed to protecting migratory birds and their natural habitats in accordance with global environmental standards and international agreements, he said.
Qurban stressed that Saudi Arabia seeks to enhance environmental sustainability in accordance with the Kingdom's Vision 2030.
'We work to monitor and protect natural environments through accurate scientific programs, including environmental exploration trips and monitoring of migratory water bird. We cooperate with national and international bodies to support strategies for protecting the environment and biodiversity,' Qurban said.
The Farasan Islands are an integrated natural environment that attracts large numbers of migratory water birds due to the diversity of their natural habitats, including mangrove forests, sandy and muddy beaches, coral rocks, and coastal salt marshes, which provide suitable places for feeding, breeding, and resting during winter migration periods.
The reserve is one of the most important natural stations for migratory water birds in Saudi Arabia. It hosts rare and endangered species during their annual migration journeys, and contributes to achieving environmental balance and enhancing biodiversity within national and international environmental protection strategies.
© Copyright 2022 The Saudi Gazette. All Rights Reserved. Provided by SyndiGate Media Inc. (Syndigate.info).
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Zawya
15-05-2025
- Zawya
Saudi Arabia to launch first space weather satellite under Artemis II mission
RIYADH — Saudi Arabia has signed a landmark agreement with the US National Aeronautics and Space Administration (NASA) to launch its first satellite dedicated to studying space weather, under the Artemis II mission. The deal marks a new milestone in Saudi–US scientific cooperation and reinforces the Kingdom's role in global space exploration initiatives. Signed during the official visit of US President Donald Trump to Riyadh, the agreement builds upon the broader US–Saudi space cooperation framework formalized in July 2024 and reflects the growing strength of bilateral ties in science, technology, and innovation. The mission, led by the Saudi Space Agency (SSA), underscores Saudi Arabia's commitment to the Artemis Accords — an international framework promoting peaceful and collaborative exploration of the Moon, Mars, and beyond. The new satellite will collect high-resolution data on solar activity and its effects on Earth's magnetic field, contributing to global efforts to protect astronauts, improve satellite navigation and communications, and enhance space weather forecasting. The initiative falls under the National Industrial Development and Logistics Program (NIDLP), a Vision 2030 realization program aimed at advancing domestic industrial content and building national expertise in strategic technologies. It also aligns with the Kingdom's goal of becoming a knowledge-driven, innovation-led economy and bolstering local talent in the growing space sector. © Copyright 2022 The Saudi Gazette. All Rights Reserved. Provided by SyndiGate Media Inc. (
Zawya
11-05-2025
- Zawya
Sandoz Egypt introduces OMNITROPE 15mg biosimilar growth hormone for the treatment of short stature
17% of Egyptian children suffer from short stature; newly available 15mg/1.5ml concentration to help expand access to growth hormone Growth hormone treatment meaningfully improves physical, social, psychological and environmental quality of life according to research¹ Cairo – Sandoz the global leader in generic and biosimilar medicines, today announced the introduction of its 15mg/1.5ml concentration of the OMNITROPE biosimilar growth hormone for the treatment of short stature to the Egyptian market, as part of its ongoing efforts to support Egypt's Vision 2030. Local healthcare authorities remain committed to addressing various health challenges to enhance public health for current and future generations, and help build a healthier, more productive workforce. Research conducted at the Suez Canal University endocrinology outpatient clinic in Ismailia City, Egypt and released in 2024, underscored the importance of short stature treatment, with findings indicating that treatment with growth hormone significantly improved physical, social, psychological, and environmental quality of life¹. 'In children and adolescents, growth hormone is used to treat growth disturbance due to insufficient secretion of growth hormone, associated with Turner syndrome, with chronic renal insufficiency, in short children/adolescents born small for gestational age, or associated with Prader-Willi syndrome (PWS). The biosynthetic/synthetic hormone is indicated for the treatment of children with growth failure due to inadequate secretion of endogenous growth hormone (GH)² ³,' Dr. Mona Salem, Professor of Paediatric Endocrinology at Ain Shams University and President of the Egyptian Society of Paediatric Endocrinology & Diabetes, said. 'Short stature is diagnosed in children or adolescents who are well below the average height for their age and gender, which may be due to genetic factors or underlying health conditions⁴ ⁵. Studies show that short stature prevalence varies geographically, with a genetic predisposition, as well as nutritional and environmental factors, playing an important role⁶,' Dr Salem added. A cross-sectional study conducted between January 2018 and January 2020 involving 33,150 Egyptian children aged 6 to 11 showed that 17% of the sample had short stature, with 40.8% attributed to familial factors and 24.2% to constitutional causes⁷. "As noted, short stature affects children and adolescents, not only physically but also psychologically. Growth hormone is one of the most effective treatments for the aforementioned growth disturbances. The dosage is carefully calculated based on weight, underlying cause, puberty stage, as well as stimulated growth hormone test results, to achieve the best possible final height outcomes," Dr. Rasha Tarif, Head of the Paediatric Endocrinology Unit at Ain Shams University and Chair of European Society for Paediatric Endocrinology (ESPE) Education and Training Committee, said. Young patients affected require therapeutic intervention to accelerate growth velocity before growth plates have fused, after which the height cannot be gained. Human growth hormone must therefore be administered during this window of opportunity to ensure a normal final adult height⁸. 'Growth hormone plays a critical role in effective treatment plans, but ensuring its availability has been a challenge in recent years. This challenge is being addressed through ongoing efforts to secure sufficient quantities to ensure uninterrupted treatment until puberty is complete, and in some cases, for life. Treatment continuity, along with proper follow-up with a specialized physician, is essential for achieving optimal results,' Dr. Tarif added. This new concentration is being made available and at an affordable cost, expanding treatment options in line with the latest global scientific standards. This will allow for a better patient response as well as an effective and safe treatment journey by minimizing interruptions. Securing the reliable availability of this human growth hormone reinforces medical efforts to provide comprehensive care for children and reflects the Egyptian medical community's commitment to delivering advanced treatment solutions for patients in need. "The Egyptian government, within the context of the Egypt Vision 2030, has shown strong commitment to reducing the prevalence of short stature among children, aiming to improve public health for current and future generations, and help build a healthier, more productive workforce, in line with the national vision for sustainable development," Sameh Elbagoury, Sandoz Egypt Country Head, said. 'Our top priority at Sandoz is to develop affordable biosimilars for high-quality biologics and ensure that as many patients as possible have access to them. Introducing the 15mg concentration of our well-established Omnitrope growth hormone allows us to help local authorities meet the increase in demand for growth hormones, reflecting the positive impact and notable success achieved by the Presidential Initiative for the Early Detection of Anaemia, Obesity and Short Stature,' Elbagoury added. Sandoz Omnitrope was approved by the US Food and Drug Administration and the European Medicines Agency in 2006 and approvals in other countries have since followed. Sandoz has also established a long-term, post-marketing surveillance program for its product to monitor its safety over time⁹. ABOUT SANDOZ Sandoz (SIX: SDZ; OTCQX: SDZNY) is the global leader in generic and biosimilar medicines, with a growth strategy driven by its Purpose: pioneering access for patients. More than 20,000 people of 100 nationalities work together to ensure 900 million patient treatments are provided by Sandoz, generating substantial global healthcare savings and an even larger social impact. Its leading portfolio of approximately 1,300 products addresses diseases from the common cold to cancer. Headquartered in Basel, Switzerland, Sandoz traces its heritage back to 1886. Its history of breakthroughs includes Calcium Sandoz in 1929, the world's first oral penicillin in 1951, and the world's first biosimilar in 2006. In 2024, Sandoz recorded net sales of USD 10.4 billion.
Zawya
23-04-2025
- Zawya
OceanQuest appoints Dr. Martin Visbeck as CEO to lead next era of deep ocean exploration
Jeddah, Kingdom of Saudi Arabia: The OceanQuest Board of Trustees proudly announces the appointment of Dr. Martin Visbeck as Chief Executive Officer. A globally recognized leader in ocean science, Dr. Visbeck brings over 30 years of pioneering expertise in advancing the understanding of the ocean's critical role within the Earth system. Dr. Visbeck's contributions span ocean discovery, research, governance, and technological innovation. His expertise is widely sought by scientific organizations, national governments, and the United Nations, underscoring his profound influence on global ocean policy. Notably, he serves on the governing board of the International Science Council (ISC) and the leadership council of the Sustainable Development Solutions Network (SDSN). He is a key contributor to several international ocean science programs and the UN Decade of Ocean Science for Sustainable Development (2021–2030). Dr. Visbeck's pioneering work in ocean science, observation and robotics has transformed data collection, discoveries and understanding in remote and challenging regions. His advocacy for digital twin technologies has enabled the development of virtual replicas of ocean systems, allowing simulation and prediction of ocean changes—critical for understanding the ocean's role in sustainable development. These groundbreaking achievements have cemented Dr. Visbeck's reputation as a global leader in advancing sustainable ocean solutions. Beyond his technical expertise, Dr. Visbeck is deeply committed to building global capacity in ocean science. He has mentored the next generation of scientists and championed inclusive training and educational opportunities worldwide. OceanQuest is a Saudi Arabian not-for-profit foundation dedicated to advancing ocean science and accelerating deep ocean exploration. The foundations goals are aligned with Saudi Arabia's Vision 2030 of fostering sustainable development, innovation and global collaboration, and positioning Saudi Arabia as a leader in ocean research and conservation. OceanQuest is set to launch a series of joint expeditions in the coming years, with a focus on studying seamounts—vital underwater ecosystems that play a critical role in the ocean's health. These missions will shed light on the biology, chemistry, physics, and geology of these ecosystems, expanding our understanding of their importance to humanity. The foundation will design and operate a fleet of cutting-edge research vessels equipped with advanced deep-sea robotics, enabling the exploration of challenging ocean depths. OceanQuest also plans to create digital twins of ocean seamounts—real-time virtual models that provide invaluable data for conservation and sustainable use, scenario planning, and decision-making. OceanQuest is committed to fostering international cooperation, inviting scientists from across the globe to participate in its initiatives to discover and understand the deep ocean. Data generated from its expeditions will be openly shared with nations and stakeholders, empowering informed decision-making and sustainable ocean stewardship. With discovery at the heart of its mission, OceanQuest seeks to inspire the next generation of ocean scientists, enhance global ocean literacy, and ignite public curiosity about the wonders of the deep ocean. Dr. Martin Visbeck, CEO of OceanQuest, said: 'OceanQuest's mission is to illuminate the ocean like never before—driving discovery, advancing scientific understanding, and supporting human progress. By investing in next generation research vessels, robotics, and advanced sensing technologies, we are strengthening the global deep ocean exploration ecosystem. Our success depends on international collaboration, uniting nations to explore, understand, safeguard and sustainably utilize the ocean's vast potential. The launch of OceanQuest marks a significant milestone in this shared journey, as we push the boundaries of exploration and make a lasting impact on the future of our planet.' In his new role, Dr. Visbeck will prioritize key initiatives that will drive OceanQuest's mission forward: Accelerate discovery of the deep ocean through deployment of capacity and research support to increase human knowledge of the ocean and seas Pioneer innovation in ocean exploration through design of new-age technology and exploration tools to accelerate the global discovery mission and contribute to blue innovation economy Create synergies in ocean discovery through influencing the setting of common goals, sharing of knowledge and enablement of KSA & nations to participate in ocean exploration Elevate public interest in the ocean and seas through multi-channel engagement to inspire new generations in driving positive change Under Dr. Visbeck's leadership, OceanQuest will advance the frontiers of ocean discovery and science, harnessing emerging technologies and fostering global partnerships to drive lasting benefits for both the environment and society. About OceanQuest: OceanQuest is a Saudi Arabian not-for-profit foundation, committed to unveiling the wonders of the ocean and exploring its secrets for the benefit of humanity. Its mission is to accelerate ocean discovery, drive innovation in the field, support global cooperation, and excite the public. OceanQuest and its global partners will launch a new era of deep ocean exploration and knowledge sharing. OceanQuest is based in the King Abdullah University of Science and Technology (KAUST) campus in Thuwal, Kingdom of Saudi Arabia. To learn more visit
